Actionable news
All posts from Actionable news
Actionable news in NVCN: NEOVASC Inc,

How These Healthcare Stocks are Performing? — Neovasc, MiMedx, InspireMD, and Amedica

The Medical Appliances and Equipment space remains a strong industry which is expected to continue growing given the high need and demand for health care and related instruments. turns investors' attention to the following stocks in review: Neovasc Inc. (NASDAQ: NVCN), MiMedx Group Inc. (NASDAQ: MDXG), InspireMD Inc. (NYSEMKT: NSPR), and Amedica Corp. (NASDAQ: AMDA). Register now and get full and free access to our downloadable research reports on these stocks at:


On Tuesday, Richmond, Canada headquartered Neovasc Inc.'s stock recorded a trading volume of 1.18 million shares, and ended the session down 5.25% at $0.55. The Company's shares have gained 6.27% in the last one month. The stock is trading 10.61% above its 50-day moving average. Moreover, shares of Neovasc, which develops, manufactures, and markets cardiovascular products worldwide, have a Relative Strength Index (RSI) of 54.48.

On August 2nd, 2016, Neovasc announced that it will release its financial results for Q2 2016 on August 9th, 2016, after markets close. The Company will subsequently hold a conference call on that same day, at 4:30 pm Eastern Time hosted by Mr. Alexei Marko, Chief Executive Officer, and Mr. Chris Clark, Chief Financial Officer. Access our complete research report on NVCN for free at:

MiMedx Group

Marietta, Georgia headquartered MiMedx Group Inc.'s stock closed the day 2.27% lower at $7.53 and with a total volume of 546,343 shares traded. The Company's shares have advanced 5.24% in the previous three months. The stock is trading 3.42% below its 50-day moving average. Additionally, shares of MiMedx Group, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues, and human skin and bone, have an RSI of 41.92.

On July 26th, 2016, MiMedx Group reported record revenue of $57.3 million for Q2 2016, an $11.6 million or 26% increase, over 2015 second quarter revenue of $45.7 million. The Company's Adjusted Gross Margin for Q2 2016 was 88.1% compared to 88.9% in Q2 2015. The company noted that Adjusted Net Income for Q2 2016 was $5.1 million, or $0.05 per diluted common share, a $749,000 decrease as compared to Adjusted Net Income of $5.9 million, or $0.05 per diluted common share, in Q2 2015. The complimentary research report on MDXG can be downloaded at: a>